Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 24:23:e934083.
doi: 10.12659/AJCR.934083.

Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease

Affiliations
Review

Prolonged Cefepime-Induced Neurotoxicity in a Patient with End-Stage Renal Disease

Dorothy Dao Nguyen et al. Am J Case Rep. .

Abstract

BACKGROUND Cefepime, a fourth-generation cephalosporin, has a known adverse effect of neurotoxicity. It occurs notably in patients with end-stage renal disease, but symptom resolution typically occurs within a median of 2 days following drug discontinuation. CASE REPORT We present a patient with end-stage renal disease on hemodialysis (TWThSat) who developed prolonged neurotoxicity lasting longer than 1 week complicated by nonconvulsive status epilepticus 2 days after cefepime discontinuation. She presented initially with a right upper-extremity arteriovenous graft infection from extended-spectrum beta-lactamase Escherichia coli, and was treated with cefepime. She eventually developed acute encephalopathy, and cefepime was discontinued. However, 2 days later, she developed seizures with worsened mental status. She was stabilized on levetiracetam and lorazepam, but developed hypotension in the Neurological Intensive Care Unit (Neuro-ICU), delaying hemodialysis. Hemodialysis was performed 6 days after cefepime discontinuation once she was stabilized, and her mental status improved 1 to 2 days after, with full improvement 20 days after admission. She was discharged on levetiracetam and meropenem. In addition, we review risk factors and symptomology of cefepime-induced neurotoxicity and discuss important management issues. CONCLUSIONS Careful attention should be paid when administering cefepime to patients with end-stage renal disease. Patients showing signs of encephalopathy should not be on cefepime any longer, and more aggressive measures may be taken, such as prompt hemodialysis, assessment of cefepime blood levels, and electroencephalogram (EEG) to monitor for signs of seizures. Prolonging hemodialysis in patients with signs of cefepime neurotoxicity can pose a danger for more serious sequelae, such as status epilepticus. Close monitoring of patients at high risk of developing adverse events from cefepime administration can ensure patient safety and well-being.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Similar articles

Cited by

References

    1. Li HT, Lee CH, Wu T, et al. Clinical, electroencephalographic features and prognostic factors of cefepime-induced neurotoxicity: A retrospective study. Neurocrit Care. 2019;31(2):329–37. - PubMed
    1. Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to β-lactam antibiotics: A literature review. Drug Safety. 2017;40(12):1171–98. - PubMed
    1. Boschung-Pasquier L, Atkinson A, Kastner LK, et al. Cefepime neurotoxicity: Thresholds and risk factors. A retrospective cohort study. Clin Microbiol Infect. 2020;26(3):333–39. - PubMed
    1. Shah M, Shah H, Maslekar A. Cefepime-induced neurotoxicity in a patient with coronary artery bypass. Indian J Pharmacol. 2016;48(5):599–600. - PMC - PubMed
    1. Nakagawa R, Sato K, Uesaka Y, et al. Cefepime-induced encephalopathy in end-stage renal disease patients. J Neurol Sci. 2017;376:123–28. - PubMed

MeSH terms